Approved indications: Nitisinone is FDA-approved, together with dietary restriction of tyrosine and phenylalanine, for treatment of hereditary tyrosinemia type 1 (HT-1) in adult and pediatric patients, and as Harliku (nitisinone) tablets to reduce urine homogentisic acid in adults with alkaptonuria (AKU).

Off-label or non-US uses: Before specific US approval for AKU, nitisinone was commonly used off-label for this condition based on European and international trial data, and ongoing research is exploring its role in other tyrosine-related disorders and as a potential mosquito-targeted malaria control tool, but these uses remain investigational rather than routine clinical practice.

Efficacy in hereditary tyrosinemia type 1: In HT-1, nitisinone plus diet usually normalizes urine and plasma succinylacetone within weeks, dramatically improves survival compared with diet alone, reduces the need for liver transplantation, and lowers the risk of liver cancer, especially when started in early infancy, though existing severe liver or kidney damage may not fully reverse.

Efficacy in alkaptonuria: In AKU, a daily oral dose of 10 mg nitisinone typically lowers urinary homogentisic acid by about 95% or more within months and, over several years, slows progression of joint and spine disease and improves pain, energy, and physical functioning, but it does not undo established structural damage.

Comparison to alternatives: Nitisinone is the only disease-modifying pharmacologic therapy for HT-1 and alkaptonuria; alternative management is largely supportive (including strict diet and pain or orthopedic care) and, for advanced HT-1, liver transplantation, so a good biochemical and clinical response to nitisinone is considered a major long-term benefit.

Typical dosing for hereditary tyrosinemia type 1 (HT-1): The usual starting dose is 0.5 mg/kg by mouth twice daily (total 1 mg/kg/day), adjusted based on weight and biochemical response up to a maximum of 2 mg/kg/day; in patients 5 years and older with undetectable urine and serum succinylacetone for at least 4 weeks on a stable dose, the total daily amount can often be given once daily.

Typical dosing for alkaptonuria: Adults with alkaptonuria are generally treated with nitisinone 10 mg by mouth once daily.

How to take it:

• Swallow tablets or capsules with water; many brands allow tablets to be crushed and mixed with a small amount of water or soft food, or capsules to be opened and mixed with water, formula, or applesauce, and oral suspensions are measured and given with the supplied oral syringe.
• Capsules are commonly taken on an empty stomach (at least 1 hour before or 2 hours after a meal), while many tablet and suspension formulations may be taken with or without food; follow the specific instructions for your brand and take doses at consistent times each day.
• Maintain the prescribed low-tyrosine, low-phenylalanine diet continuously, including careful control of protein intake and avoidance of aspartame-containing products when recommended.

Special dosing instructions and monitoring: Dose adjustments are typically guided by regular measurements of urine or plasma succinylacetone (HT-1), urine homogentisic acid (alkaptonuria), liver function tests, alpha-fetoprotein (for liver cancer risk in HT-1), and plasma tyrosine levels; high tyrosine is usually managed by tightening diet rather than by lowering the nitisinone dose.

Missed dose: If a dose is missed, it should be taken as soon as remembered unless it is close to the next scheduled dose, in which case the missed dose should be skipped and the regular dosing schedule resumed without taking a double dose.

Overdose: Taking more nitisinone than prescribed can lead to very high tyrosine levels and more severe eye, skin, or neurologic problems; emergency medical evaluation or immediate contact with a poison control center is recommended if an overdose is suspected.

Common side effects: The most frequent problems are related to elevated blood tyrosine caused by nitisinone and include eye irritation or redness, light sensitivity, eye pain, blurry vision, headaches, dry or itchy skin, and thickened skin on the palms or soles; mild decreases in platelets or white blood cells, nausea, vomiting, decreased appetite, and fatigue can also occur, typically developing in the first months of therapy or after diet lapses and improving when tyrosine levels are brought under control.

Serious or rare adverse effects needing urgent attention:

• Severe eye symptoms (sudden change in vision, intense eye pain, very red eyes, or corneal ulcers).
• Unusual bruising or bleeding, frequent infections, or marked tiredness suggesting significant drops in platelets or white blood cells.
• Severe or painful thick skin plaques on hands or feet, or other serious skin reactions.
• Signs of liver injury such as yellowing of the skin or eyes, dark urine, or strong upper abdominal pain, or sudden neurologic changes like confusion, difficulty walking, or seizures.
• Any signs of a severe allergic reaction, including swelling of the face, lips, tongue, or throat or trouble breathing.

Warnings and precautions: Nitisinone must be used with a low-tyrosine, low-phenylalanine diet and regular monitoring of blood tyrosine to limit eye, skin, and neurologic toxicity; in pregnancy it should be used only if the expected benefit outweighs potential fetal risk, and breastfeeding is generally discouraged because of concerning animal data; it is approved for HT-1 at all ages but for AKU only in adults, and people with significant liver or kidney impairment, pre-existing eye disease, or abnormal blood counts require closer follow-up and possible dose or diet adjustments.

Overall safety compared with other options: When diet is carefully followed and monitoring is consistent, nitisinone is usually well tolerated long term, with serious adverse events relatively uncommon compared with the high risk of progressive organ damage without treatment in HT-1 or AKU.

Side-effect reporting and safety updates: Side effects can be reported to the FDA MedWatch program (online or by calling 1-800-FDA-1088), and the most current safety information is provided in the latest prescribing information and on FDA and manufacturer websites for each nitisinone product.

Prescription and OTC drug interactions: Nitisinone moderately inhibits the liver enzyme CYP2C9 and can increase blood levels of medicines that depend on this pathway, such as warfarin, phenytoin, some sulfonylurea diabetes drugs, and certain NSAIDs, and it has weaker effects on CYP2E1 and the kidney transporters OAT1 and OAT3 (affecting drugs like furosemide), so doses of these co-medications may need adjustment and closer clinical or laboratory monitoring.

Foods, supplements, and alcohol: Because the drug causes tyrosine to accumulate, patients should limit foods and supplements high in tyrosine or phenylalanine and avoid or strictly limit aspartame-containing products when advised, as aspartame contains phenylalanine; alcohol has no specific interaction with nitisinone but can worsen underlying liver disease or mask side effects, so heavy drinking is generally discouraged.

Co-morbid conditions and other precautions: Extra caution is needed when nitisinone is combined with medicines that suppress bone marrow (such as some chemotherapy or immunosuppressive agents) or increase bleeding risk, since nitisinone can rarely lower platelets or white blood cells; people with pre-existing eye disorders may be more vulnerable to tyrosine-related ocular problems and require more frequent ophthalmologic follow-up.

Monitoring requirements:

• Regular blood and/or urine tests for succinylacetone (HT-1), homogentisic acid (alkaptonuria), plasma tyrosine, liver function, kidney function, and complete blood counts to adjust dosing and detect toxicity early.
• Periodic eye examinations, often including slit-lamp evaluations, to identify corneal or other ocular changes before they cause lasting vision problems.
• Ongoing imaging and clinical assessments of liver status in HT-1 and of the spine and large joints in alkaptonuria to track disease progression and treatment benefit.

Q: What conditions is nitisinone prescribed to treat?
A: It is used to treat hereditary tyrosinemia type 1 in adults and children and to reduce homogentisic acid levels in adults with alkaptonuria, both of which are rare genetic disorders of tyrosine breakdown.

Q: How long will I need to take nitisinone?
A: For both hereditary tyrosinemia type 1 and alkaptonuria, treatment is usually long term and often lifelong to keep toxic substances controlled and prevent disease progression.

Q: When will I notice improvement after starting nitisinone?
A: Laboratory markers such as succinylacetone or homogentisic acid often improve within weeks to months, while clinical benefits like better growth in HT-1 or reduced pain and stiffness in alkaptonuria may take many months to several years to become clear.

Q: Do I still need a special diet while taking nitisinone?
A: Yes, people treated for HT-1 and often those with alkaptonuria must follow a carefully controlled low-tyrosine, low-phenylalanine diet to prevent excessively high blood tyrosine levels and reduce the risk of eye, skin, and neurologic side effects.

Q: Will I need regular blood tests and eye exams on this medicine?
A: Most patients have periodic blood and urine tests to monitor toxic metabolites, liver and kidney function, blood counts, and tyrosine levels, as well as regular eye examinations to detect corneal changes early.

Q: Can nitisinone reverse existing liver or joint damage?
A: Nitisinone can strongly slow or prevent further damage and greatly improve long-term outcomes, but it usually cannot fully repair severe liver scarring, advanced joint destruction, or spinal changes that are already present when treatment starts.

Storage: Store nitisinone tablets, capsules, or oral suspension at room temperature away from excess heat, moisture, and light; some capsule or suspension brands may require refrigeration before first use or have specific room-temperature time limits, so follow the instructions on your product label, keep the container tightly closed, and always store it out of the reach of children.

Disposal: Dispose of unused or expired nitisinone through a pharmacy or community drug take-back program when possible; if none is available, mix tablets or capsule contents (not the open suspension bottle) with an undesirable substance such as used coffee grounds or cat litter in a sealed bag or container before placing it in household trash, and do not flush the medication unless the label specifically instructs you to do so.